Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL

Journal of Immunology

Volumn 165, Issue 11, 2000, Pages 6454-6462

  Belyakov, I M ^a   Ahlers, J D ^a   Clements, J D ^a   Strober, W ^a   Berzofsky, J A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BACTERIAL TOXIN; CHOLERA TOXIN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ESCHERICHIA COLI; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS TRANSMISSION;

EID: 0034544623     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.11.6454     Document Type: Article

References (71)

1. + cytotoxic T lymphocytes for resistance to mucosal-viral transmission in mice and enhancement of resistance by local administration of IL-12
2. Selective induction of protective MHC class I restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa
3. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi
4. + lymphocytes
5. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
6. Broadly cross-reactive HIV-specific cytotxic T-lymphocytes in highly-exposed persistently seronegative donors
7. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
8. + T cell depletion in simian immunodeficiency virus-infected macaques
9. Antigen sampling across epithelial barriers and induction of mucosal immune responses
10. Genital mucosal transmission of simian immunodeficiency virus: Animal model for heterosexual transmission of human immunodeficiency virus
11. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques
12. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein
13. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
14. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
15. Approaches to improve engineered vaccines for human immunodeficiency virus (HIV) and other viruses that cause chronic infections
16. A rational basis for mucosal vaccination against HIV infection
17. Mucosal immunity and tolerance: Relevance to vaccine development
18. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge
19. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: GM-CSF and TNFα synergize with IL-12 to enhance induction of CTL
20. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines
21. Role of mucosal adjuvants in mucosal immunization
22. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor B1 and B2 chain expression
23. The mechanism of cholera toxin adjuvanticity
24. Cholera toxin as a mucosal adjuvant
25. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin
26. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity
27. Approaches to improve engineered HIV vaccine which induce mucosal immunity
28. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants
29. Effectiveness of intranasal immunization with HIV-gp160 Env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G)
30. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT)
31. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
32. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis
33. LT(R192G), a nontoxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp
34. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge
35. Heat-labile enterotoxin from Escherichia coli as an adjuvant for oral influenza vaccination
36. Safety and immunogenicity in volunteers of a new candidate oral mucosal adjuvant, LT(R192G)
37. Safety and enhanced immunogenicity in volunteers of an oral, inactivated whole cell Campylobacter vaccine co-administered with a modified E. coli heat-labile enterotoxin adjuvant - LT(R192G)
38. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations
39. Construction of peptides encompassing multideterminant clusters of HIV envelope to induce in vitro T-cell responses in mice and humans of multiple MHC types
40. An immunodominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes
41. Candidate HIV type1 multideterminant cluster peptide-P18MN vaccine constructs elicit type1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization
42. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence
43. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia vires expressing HIV 89.6 envelope protein
44. Broad recognition of cytotoxic T-cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules
45. Serum angiotensin-1 converting enzyme activity processes an HIV 1 gp160 peptide for presentation by MHC class I molecules
46. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule
47. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity
48. A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles
49. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
50. Proinflammatory and immunoregulatory functions of interleukin-12
51. New insights and approaches regarding B- and T-cell epitopes in HIV vaccine design
52. The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions
53. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
54. Site-specific mutagenesis of the catalytic subunit of cholera toxin: Substituting lysine for arginine 7 causes loss of activity
55. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit
56. Inactivation of the Escherichia coli heat-labile enterotoxin by in vitro mutagenesis of the A-subunit gene
57. Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs
58. Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin
59. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity
60. Mutation of a buried residue causes loss of activity but no conformational change in the heat-labile enterotoxin of Escherichia coli
61. Interaction of ADP-ribosylation factor with Escherichia coli enterotoxin that contains an inactivating lysine 112 substitution
62. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis
63. Glutamic acid-112 of the A subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli is important for ADP-ribosyltransferase activity
64. A single amino acid substitution in the A subunit of Escherichia coli enterotoxin results in a loss of its toxic activity
65. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity
66. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant
67. The adjuvant effect of a nontoxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal coimmunization with a synthetic peptide
68. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
69. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells
70. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4
71. Helper T cell subsets for immunoglobulin A responses: Oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues